# Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

> **NCT02206295** · PHASE1 · COMPLETED · sponsor: **Actelion** · enrollment: 80 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** selexipag

## Key facts

- **NCT ID:** NCT02206295
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206295, "Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02206295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*